Global Non-Cystic Fibrosis Bronchiectasis Market
$4.8 Bn Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity and Forecasts, 2019-2029F
05 juil. 2024 10h23 HE | Research and Markets
Dublin, July 05, 2024 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to ...
Polarean_color_black.png
Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
20 juin 2024 09h15 HE | Polarean
DURHAM, NC and LONDON, June 20, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance...
Polarean_color_black.png
Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference
08 mai 2024 09h02 HE | Polarean
DURHAM, NC and LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX),  a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, has been selected...
Polarean_color_black.png
Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs
08 sept. 2023 08h02 HE | Polarean
Durham, NC and London, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, announced today it...
Polarean_color_black.png
CMS grants reimbursement code for the Polarean XENOVIEW™ MRI Technology
29 août 2023 08h10 HE | Polarean
Durham, NC, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX), a commercial-stage medical device leader in advanced MRI scanning of the lungs, announces that the Centers for Medicare...
Avalyn-Logo-FINAL.png
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
07 août 2023 08h00 HE | Avalyn Pharma Inc.
Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
Polarean_color_black.png
Polarean Receives Clearance for New MRI Chest Coil
03 août 2023 08h08 HE | Polarean
Durham, NC, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Polarean (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced MRI scanning of the lungs, announces it has...
Avalyn-Logo-FINAL.png
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
15 juin 2023 08h00 HE | Avalyn Pharma Inc.
SEATTLE, June 15, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn-Logo-FINAL.png
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
11 avr. 2023 08h00 HE | Avalyn Pharma Inc.
Seattle, April 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company developing inhaled therapies to treat life-threatening pulmonary diseases, today reported...
Avalyn-Logo-FINAL.png
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
23 mars 2023 13h23 HE | Avalyn Pharma Inc.
SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...